share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股东委托书决议
美股sec公告 ·  04/26 06:13
Moomoo AI 已提取核心信息
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 13, 2024, at 1:00 p.m. Pacific Time. The proxy statement outlines several key proposals, including the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000. The company, which was incorporated as Locust Walk Acquisition Corp. and underwent a business combination to become eFFECTOR Therapeutics, Inc., is inviting stockholders to attend the meeting online and cast their votes on these matters. The proxy materials are available on the Internet as part of the company's efforts to reduce environmental impact and delivery costs.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 13, 2024, at 1:00 p.m. Pacific Time. The proxy statement outlines several key proposals, including the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000. The company, which was incorporated as Locust Walk Acquisition Corp. and underwent a business combination to become eFFECTOR Therapeutics, Inc., is inviting stockholders to attend the meeting online and cast their votes on these matters. The proxy materials are available on the Internet as part of the company's efforts to reduce environmental impact and delivery costs.
生物制药公司Effector Therapeutics, Inc. 宣布已向美国证券交易委员会（SEC）提交即将举行的2024年年度股东大会的最终委托书（DEF 14A）。该会议定于太平洋时间2024年6月13日下午 1:00 以虚拟方式举行。委托书概述了几项关键提案，包括选举两名三类董事，批准安永会计师事务所作为截至2024年12月31日的财政年度的独立注册会计师事务所，以及批准将普通股授权数量从4000万股增加到8000万股的修正案。该公司注册为Locust Walk Acquisition Corp.，并进行了业务合并，成为Effector Therapeutics, Inc.，该公司邀请股东参加在线会议并就这些问题进行投票。代理材料可在互联网上获得，这是该公司减少环境影响和交付成本的努力的一部分。
生物制药公司Effector Therapeutics, Inc. 宣布已向美国证券交易委员会（SEC）提交即将举行的2024年年度股东大会的最终委托书（DEF 14A）。该会议定于太平洋时间2024年6月13日下午 1:00 以虚拟方式举行。委托书概述了几项关键提案，包括选举两名三类董事，批准安永会计师事务所作为截至2024年12月31日的财政年度的独立注册会计师事务所，以及批准将普通股授权数量从4000万股增加到8000万股的修正案。该公司注册为Locust Walk Acquisition Corp.，并进行了业务合并，成为Effector Therapeutics, Inc.，该公司邀请股东参加在线会议并就这些问题进行投票。代理材料可在互联网上获得，这是该公司减少环境影响和交付成本的努力的一部分。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息